Parkinson's Disease Market will upsurge due to the increasing prevalent population and the launch of gene therapies and several other potential therapies
LAS VEGAS, April 14, 2021 /PRNewswire/ -- DelveInsight's "Parkinson's Disease Market" report provides a thorough comprehension of the Parkinson's Disease, historical and forecasted epidemiology, and the Parkinson's Disease market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Parkinson's Disease market report also proffers an analysis of the current Parkinson's Disease treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
The increase in Parkinson 's disease prevalent population in the 7MM and the expected entry of premium price assets will influence market size growth.
In February 2021, the US FDA approved GOCOVRI (amantadine) as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes. It is also approved to treat dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
In May 2020, the US FDA approved KYNMOBI (apomorphine HCI) sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in Parkinson's Disease patients.
Levodopa is the most preferred therapy for Parkinson's Disease treatment and its symptoms.
The US FDA, in April 2020, has approved Ongentys (Opicapone) as an oral, add-on daily treatment for Parkinson's disease patients experiencing off periods while on a levodopa/carbidopa regime.
Other than levodopa, dopamine agonists followed by amantadine, MAO-B inhibitors, and several others (COM-T inhibitors, anticholinergic inhibitors) accounted for the Parkinson's Disease significant market share in the US in 2017.
A strong pipeline of drugs is being developed by the manufacturers such as Prevail Therapeutics, Axovant Gene Therapies, Denali Therapeutics, Luye Pharma, Sumitomo Dainippon Pharma, BIAL, AbbVie, Impax Laboratories (Amneal Pharmaceuticals), Supernus Pharmaceuticals, Intec Pharma, MeiraGTx Limited, Axovant Sciences, NeuroDerm, Intracellular Therapies, Integrative Research Laboratories AB (IRLAB), International Stem Cell Corporation, Living Cell Technologies, Pharma Two B Ltd, and others that will offer lucrative opportunities for the Parkinson's disease market to grow.
Parkinson's Disease is a progressive disorder caused by degeneration of nerve cells in the substantia nigra, which controls movement. Most people start developing Parkinson's Disease symptoms when they are over 50, although some individuals experience symptoms when under 40.
According to DelveInsight's analysts, the total diagnosed Parkinson's Disease prevalent population in the 7MM is expected to rise to 3,284,084 cases in 2030 during the study period [2018–2030]. In 2020, the US accounted for 38.36% of the total diagnosed prevalent cases of Parkinson's Disease in the 7MM. The males appear to be predisposed to Parkinson's Disease, so a higher percentage of prevalence was observed in males than females.
There is currently no cure, but treatments are available to help relieve Parkinson's Disease symptoms. These treatments include medication, surgery, complementary and supportive therapies (such as diet, exercise, physical therapy, occupational therapy, and speech therapy).
The approved medication therapies are categorised into seven groups that comprise Levodopa, Carbidopa-levodopa infusion (Duodopa), Dopamine agonists (Mirapex, Requip, Neupro), MAO B inhibitors (Zelapar, Azilect, Xadago), Catechol O-methyltransferase (COMT) inhibitors (Tasmar, Comtan), Anticholinergics (Cogentin, Artane), and Amantadine.
Medication can be utilised to improve the main symptoms of Parkinson's Disease. But not all the medications available are helpful for everyone, and the short- and long-term effects are different. Three main types of medication are usually used: Carbidopa-levodopa, Carbidopa-levodopa infusion, and Dopamine agonists.
Treatment with monoamine oxidase-B (MAO-B) inhibitors, amantadine (Symmetrel), or anticholinergics may improve mild symptoms; but, most patients require levodopa or a dopamine agonist. The American Academy of Neurology (AAN) recommends levodopa or a dopamine agonist when dopaminergic treatment is needed, depending on the need to improve motor disability or decrease motor complications (dopamine agonists cause fewer motor complications). The most often prescribed combination drugs are carbidopa/levodopa (cocareldopa [sinemet, pharmacopa, atamet]) and benserazide/levodopa (co-beneldopa [Madopar]). Levodopa with a DOPA decarboxylase inhibitor is mostly a first-line treatment option for Parkinson's Disease.
For advanced Parkinson's Disease patients, mostly surgeries are preferred. Most of the treatments are aimed at benefiting the tremor or rigidity that emerges from the disease. In some patients, surgery may reduce the amount of medication that is required to control the symptoms. Three types of surgeries may be performed for Parkinson's disease, including the following: Lesion surgery, deep brain stimulation (DBS), and neural grafting or tissue transplants. Deep brain stimulation was approved in 2002 as adjunctive therapy in reducing motor fluctuation in advanced Parkinson disease.
Allo iPS cell-derived dopamine neural progenitor: Sumitomo Dainippon Pharma
AAV-GAD: MeiraGTx Limited
AXO-Lenti-PD (OXB-102): Axovant Sciences
Lenrispodun (ITI-214): Intracellular Therapies
Pirepemat (IRL752): Integrative Research Laboratories AB (IRLAB)
PR001: Prevail Therapeutics
ISC-hpNSC: International Stem Cell Corporation
And several others.
In conclusion, the development of adherence-friendly drug formulations, development of the drug for better treatment of motor symptoms, and gene therapy and stem cell therapy will drive Parkinson's Disease Market Growth, whereas inadequate knowledge of Parkinson's Disease pathophysiology, lack of diagnostic measures and methods, and lack of efficacy of existing therapies will hamper the growth of Parkinson's Disease market size.
DelveInsight's Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Parkinson's disease psychosis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Parkinson's Disease - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Parkinson's Disease in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight's Parkinson's disease psychosis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Parkinson's disease psychosis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Parkinson's disease psychosis Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Parkinson's disease psychosis market.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.